CTI & Glycosan deals:
They did pay 250k plus 261,959 shares for CTI.
And for Glycosan stockholders will receive a total consideration of around 332,906 BioTime common shares, and warrants to purchase around 206,612 additional BioTime common shares at an exercise price of $10 per share. BioTime will assume Glycosan’s obligations, which at January 31, 2011 totaled approximately $218,000.
I feel they bought some quality technology and West does well on his deals. These acquisitions combined with BioTime’s stem cell technologies, give BioTime and its subsidiaries a broad manufacturing platform.
The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or "painting" these peptides onto the surfaces of therapeutic cells using techniques that do not modify the cell physiology, CTI has produced tissue-specific and disease-specific cell modification agents with potential to take cell therapy products to a new level of performance.
Glycosan has been a leader in developing, manufacturing, and marketing proprietary biocompatible hydrogels that mimic the extracellular matrix (ECM). The ECM is an important and complex mixture of macromolecules that holds cells together in tissues and organs and performs many other important functions. The acquired products have the ability to support the growth and directed differentiation of stem cells and are designed as implantable, resorbable matrices for tissue engineering, regenerative medicine, and for research applications involving the laboratory culture of human cells.
These two acquisitions make BioTime stronger. The prices paid for each company do not seem pricey to me at all for what they are receiving. I am happy the pps pulled back under 7.50 because it was my buy back in target, but it can go lower, if it does I look at it as a gift to buy more shares at a discounted price. But it also seems to want to move up churning between $7 & $7.50 the past couple days. Buy in increments so either way it goes you make out, thats my plan. I will stick by my $15 target even though analysts at BioLogic Equity Research set a “sell” rating and a $2.00 price target on the stock, they just want the downtrend to continue so they get to buy shares on the cheap before the inevitable price appreciation and who are they? Either way I own shares of a company that in my opinion will be a leader in science and medicine. Like I posted before you have to own an interest in anything Lanza, Kierstead and West are involved in. I am currently researching Dr. Anthony Atala too. I hope this helps you decide to get in where you feel comfortable because this company looks to me like a winner. Time will tell
